PMC:7161517 / 399-757 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":278,"end":291},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"}],"text":"on; increased ACE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiova"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":19,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T3","span":{"begin":208,"end":211},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"on; increased ACE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiova"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":77,"end":91},"obj":"Chemical"},{"id":"T7","span":{"begin":77,"end":88},"obj":"Chemical"},{"id":"T8","span":{"begin":89,"end":91},"obj":"Chemical"},{"id":"T9","span":{"begin":111,"end":125},"obj":"Chemical"},{"id":"T10","span":{"begin":115,"end":125},"obj":"Chemical"},{"id":"T11","span":{"begin":131,"end":148},"obj":"Chemical"},{"id":"T12","span":{"begin":158,"end":169},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_25354"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"on; increased ACE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiova"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T14","span":{"begin":14,"end":18},"obj":"G_3;PG_10;PR:000003622"},{"id":"T15","span":{"begin":77,"end":91},"obj":"DG_37;PR:000001118"},{"id":"T16","span":{"begin":92,"end":100},"obj":"PR:000001118"},{"id":"T17","span":{"begin":115,"end":125},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T18","span":{"begin":131,"end":148},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T19","span":{"begin":149,"end":169},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T20","span":{"begin":179,"end":183},"obj":"PR:000003622;G_3;PG_10"},{"id":"T21","span":{"begin":193,"end":203},"obj":"GO:0010467"},{"id":"T22","span":{"begin":256,"end":262},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T23","span":{"begin":278,"end":283},"obj":"NCBITaxon:10239"},{"id":"T60166","span":{"begin":14,"end":18},"obj":"G_3;PG_10;PR:000003622"},{"id":"T39187","span":{"begin":77,"end":91},"obj":"DG_37;PR:000001118"},{"id":"T33501","span":{"begin":92,"end":100},"obj":"PR:000001118"},{"id":"T28542","span":{"begin":115,"end":125},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T14634","span":{"begin":131,"end":148},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T38268","span":{"begin":149,"end":169},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T7996","span":{"begin":179,"end":183},"obj":"PR:000003622;G_3;PG_10"},{"id":"T85494","span":{"begin":193,"end":203},"obj":"GO:0010467"},{"id":"T23807","span":{"begin":256,"end":262},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T85043","span":{"begin":278,"end":283},"obj":"NCBITaxon:10239"}],"text":"on; increased ACE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiova"}

{"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":14,"end":18},"obj":"Gene"},{"id":"26","span":{"begin":111,"end":114},"obj":"Gene"},{"id":"27","span":{"begin":131,"end":157},"obj":"Gene"},{"id":"28","span":{"begin":179,"end":183},"obj":"Gene"},{"id":"34","span":{"begin":336,"end":344},"obj":"Species"},{"id":"37","span":{"begin":278,"end":291},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"Gene:59272"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Gene:1636"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Gene:4306"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Gene:59272"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:9606"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"on; increased ACE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 receptor expression, it has been tacitly believed that the use of these agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiova"}